Abstract
This study was designed to assess the influence of highly active antiretroviral therapy (HAART) on non-Hodgkin lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV). Within EuroSIDA, a multicenter observational cohort of more than 8500 patients from across Europe, the incidences of NHL and subtypes (Burkitt, immunoblastic, primary brain lymphoma [PBL], and other/unknown histology) were determined according to calendar time of follow-up, and for those who initiated HAART (≥3 drugs) also time on HAART. Potential predictive factors of NHL were evaluated in Cox proportional hazard models. Over 26 764 person-years of prospective follow-up (PYF) from May 1994 to December 2000, the incidence of NHL decreased from 1.99 (95% confidence interval, 1.51-2.47) before September 1995 to 0.30 (0.19-0.42) cases/100 (PYF) after March 1999 (P
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Cite
CITATION STYLE
Kirk, O., Pedersen, C., Cozzi-Lepri, A., Antunes, F., Miller, V., Gatell, J. M., … Barton, S. E. (2001). Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood, 98(12), 3406–3412. https://doi.org/10.1182/blood.V98.12.3406
Readers' Seniority
Readers' Discipline
